Baird analyst Joel Beatty downgraded Arcturus Therapeutics to Underperform from Neutral with an $18 price target. Post the Q3 results, the analyst has decreased conviction in the company’s lead program ARCT-810 considering newly delayed timelines. And while the collaboration with CSL Sequiris last week provides a nice $200M upfront payment, it is "highly uncertain" whether future milestones to Arcturus will meaningfully exceed the company’s required costs, Beatty tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARCT:
- Biotech Alert: Searches spiking for these stocks today
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Fly Intel: Pre-market Movers
- Arcturus Therapeutics upgraded to Equal Weight from Underweight at Barclays
- Arcturus Therapeutics price target raised to $44 from $39 at Cantor Fitzgerald
